BD Diagnostic Systems, Sparks, MD, announces the immediate availability of BD BBL™ GC-Lect™ Agar, a selective plated medium that provides enhanced growth and recovery of Neisseria gonorrhoeae. BD BBL™ GC-Lect™ Agar was created by BD in order to provide the additional inhibition required to prevent overgrowth of the pathogenic variety of Neisseria in specimens containing Capnocytophaga species. The improved inhibition and selectivity of BD BBL™ GC-Lect™ Agar comes from its combination of five antimicrobial agents that inhibit gram-positive bacteria, including vancomycin-resistant S. epidermidis, gram-negative species like Proteus and Capnocytophaga, as well as fungi including Candida albicans.

Because BBL GC-Lect Agar actually contains a decreased concentration of vancomycin, it permits the growth of some vancomycin-sensitive gonococcal strains that are inhibited on standard Modified Thayer-Martin (MTM) Agar. In a clinical evaluation of 500 samples, visible growth of N. gonorrhoeae occurred within 24 hours in 72% of the positive cultures on BBL GC-Lect Agar, compared with only 52% in the reference medium, MTM Agar.

This product is available in 100 mm-style Stacker™ plate packs of 20 or 100 and JEMBEC™ CO₂-generating plates in packs of 10. For more information or to receive an evaluation sample, please contact your local BD representative, or call 1-800-638-8663.

JEMBEC is a trademark of Miles Scientific
BD, BBL, GC-Lect and Stacker are trademarks of Becton, Dickinson and Company. © 2002 BD
August 2002

This press release may contain certain forward-looking statements (as defined under Federal securities laws) regarding BD's performance, including future revenues, products and income, or events or developments that BD expects to occur or anticipates occurring in the future. All such statements are based upon current expectations of BD and involve a number of business risks and uncertainties. Actual results could vary materially from anticipated results described, implied or projected in any forward-looking statement. Factors that could cause actual results to vary materially from any forward-looking statement include, but are not limited to: competitive factors; pricing and market share pressures; changes in interest or foreign currency exchange rates; difficulties inherent in product development and delays in product introductions; changes in regional, national or foreign economic conditions; increases in energy costs; fluctuations in costs and availability of raw materials and in BD's ability to maintain favorable supplier arrangements and relationships; and changes in healthcare or other governmental regulation; issuance of new or revised accounting standards, as well as other factors discussed in this press release and in BD's filings with the Securities and Exchange Commission. We do not intend to update any forward-looking statements to reflect events or circumstances after the date hereof except as required by applicable laws or regulations.